A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of HRS-3095 in Healthy Participants
Sponsor study identifier
interventional
36
1 country
1
Study Start
July 27, 2026
Actual (reported)Primary Completion
October 16, 2026
Actual (reported)Study Completion
October 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The purpose of this study is to assess safety, PK, Pharmacodynamic profile of a single dose of HRS-3095 in healthy participants
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 22, 2026
Actual (reported)July 7, 2026
Actual (reported)July 27, 2026
Actual (reported)October 16, 2026
Actual (reported)October 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse Events
Number of participants with Adverse events and Serious adverse events
Day 8
PK Profile of HRS-3095 After a Single-Dose Administration, Pharmacokinetics - Cmax
Day 4
PK Profile of HRS-3095 After a Single-Dose Administration, Pharmacokinetics - AU0-inf
Day 4
PK Profile of HRS-3095 After a Single-Dose Administration, Pharmacokinetics - Tmax
Day 4
PK Profile of HRS-3095 After a Single-Dose Administration, Pharmacokinetics - t½
Day 4
PD Profile of HRS-3095 After a Single dose administration:
Day 8
Single dose HRS-3095 /placebo given orally
Single dose HRS-3095 /placebo given orally
Single dose HRS-3095 /placebo given orally
Single dose HRS-3095 /placebo given orally - Dose level 1
Single dose HRS-3095 /placebo given orally - Dose level 2
Veritus Research
Bayswater, Victoria, 3153, Australia
First Submitted
June 22, 2026
First Posted
July 7, 2026
Study Start
July 27, 2026
Actual (reported)Primary Completion
Single dose HRS-3095 /placebo given orally - Dose level 3
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
October 16, 2026
Study Completion
October 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
October 30, 2026
Record last verified: 2026-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: